Which sponsor classes are worst on rate, and which are biggest on stock?

Project

The key distinction on this page is between systematic opacity and absolute hidden stock, because the class with the worst rate is not the class with the biggest backlog.

Open dashboard at root Read E156 micro-paper Open protocol Open series hub

OTHER_GOV is worst on rate. OTHER is worst on stock. Industry is still too large to ignore.

Class comparison

A standalone E156 project comparing sponsor classes on rate, stock, and structural sparsity rather than flattening everything into one leaderboard.

Worst rate

95.7%

OTHER_GOV

Largest stock

127,704

OTHER

Industry stock

44,007

Still material

NIH score

4.05

Highest named-class mean

Rate versus stock

OTHER dominates by unresolved stock, but OTHER_GOV is worse on the eligible rate metric.

This is why the project is split: the biggest class by stock is not the same class that looks worst when evaluated as a rate among eligible older studies.

Read Across Projects

Across The Series

The split projects are meant to be read together: one for industry, one for sponsor classes, one for phases, and one for structural missingness.

Industry Disclosure Gap

CT.gov Industry Disclosure Gap

A standalone E156 project on how much long-past non-disclosure and structural sparsity remain inside industry-linked ClinicalTrials.gov records.

Phase Reporting Gap

CT.gov Phase Reporting Gap

A standalone E156 project on how reporting gaps change by trial phase, showing that phase structure matters alongside sponsor class.

Structural Missingness

CT.gov Structural Missingness

A standalone E156 project on the descriptive fields that disappear from ClinicalTrials.gov even before results reporting is considered.